Venous (Vein) Thrombosis - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 91 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Venous (Vein) Thrombosis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Venous (Vein) Thrombosis - Pipeline Review, H2 2014', provides an overview of the Venous (Vein) Thrombosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Venous (Vein) Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous (Vein) Thrombosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Venous (Vein) Thrombosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Venous (Vein) Thrombosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Venous (Vein) Thrombosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Venous (Vein) Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Venous (Vein) Thrombosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Venous (Vein) Thrombosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Venous (Vein) Thrombosis Overview 8
Therapeutics Development 9
Pipeline Products for Venous (Vein) Thrombosis - Overview 9
Pipeline Products for Venous (Vein) Thrombosis - Comparative Analysis 10
Venous (Vein) Thrombosis - Therapeutics under Development by Companies 11
Venous (Vein) Thrombosis - Therapeutics under Investigation by Universities/Institutes 13
Venous (Vein) Thrombosis - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Venous (Vein) Thrombosis - Products under Development by Companies 17
Venous (Vein) Thrombosis - Products under Investigation by Universities/Institutes 18
Venous (Vein) Thrombosis - Companies Involved in Therapeutics Development 19
Bayer AG 19
Bristol-Myers Squibb Company 20
Eisai Co., Ltd. 21
F. Hoffmann-La Roche Ltd. 22
Generex Biotechnology Corporation 23
GlycoMimetics, Inc. 24
Merrion Pharmaceuticals Plc 25
Regado Biosciences, Inc. 26
Venous (Vein) Thrombosis - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
AB-012 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
apixaban - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
BAY-1213790 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
BMS-593214 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
E-5539 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ER-410660 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
fondaparinux sodium - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
GMI-1271 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ichorcumab - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Low Molecular Weight Heparin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
NPB-06 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
REG-2 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
rivaroxaban - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
RNAi Oligonucleotide for DVT - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecules for Hematological Disorders and Cancer - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
TRX-1 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Venous (Vein) Thrombosis - Recent Pipeline Updates 58
Venous (Vein) Thrombosis - Dormant Projects 77
Venous (Vein) Thrombosis - Discontinued Products 78
Venous (Vein) Thrombosis - Product Development Milestones 79
Featured News & Press Releases 79
Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE 79
Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy 79
Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 81
Jun 27, 2014: Eliquis (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 83
Mar 14, 2014: U.S. FDA Approves Eliquis (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery 84
Dec 19, 2013: FDA Accepts For Review ELIQUIS Supplemental New Drug Application For The Treatment Of Deep Vein Thrombosis And Pulmonary Embolism, And For The Reduction In The Risk Of Recurrent DVT And PE 85
Sep 20, 2013: Pooled Analysis Confirms XARELTO has Similar Efficacy and Reduces the Incidence of Major Bleeding by Nearly Half Compared to Standard of Care in Treatment of DVT and PE 85
Sep 03, 2013: Bayer Partners with Thrombosis Research Institute in a Major Global Registry to Drive Improved Outcomes in Patients Suffering from Deep Vein Thrombosis or Pulmonary Embolism 87
Jul 11, 2013: FDA Accepts Eliquis Supplemental New Drug Application for Review for Prophylaxis of Deep Vein Thrombosis Following Hip Or Knee Replacement Surgery 89
Jun 26, 2013: Bayer's Xarelto Receives Positive Recommendation From NICE As New Treatment Option For Pulmonary Embolism And Deep Vein Thrombosis 89
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 91
Disclaimer 91

List of Tables
Number of Products under Development for Venous (Vein) Thrombosis, H2 2014 9
Number of Products under Development for Venous (Vein) Thrombosis - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Venous (Vein) Thrombosis - Pipeline by Bayer AG, H2 2014 19
Venous (Vein) Thrombosis - Pipeline by Bristol-Myers Squibb Company, H2 2014 20
Venous (Vein) Thrombosis - Pipeline by Eisai Co., Ltd., H2 2014 21
Venous (Vein) Thrombosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 22
Venous (Vein) Thrombosis - Pipeline by Generex Biotechnology Corporation, H2 2014 23
Venous (Vein) Thrombosis - Pipeline by GlycoMimetics, Inc., H2 2014 24
Venous (Vein) Thrombosis - Pipeline by Merrion Pharmaceuticals Plc, H2 2014 25
Venous (Vein) Thrombosis - Pipeline by Regado Biosciences, Inc., H2 2014 26
Assessment by Monotherapy Products, H2 2014 27
Number of Products by Stage and Target, H2 2014 29
Number of Products by Stage and Mechanism of Action, H2 2014 31
Number of Products by Stage and Route of Administration, H2 2014 33
Number of Products by Stage and Molecule Type, H2 2014 35
Venous (Vein) Thrombosis Therapeutics - Recent Pipeline Updates, H2 2014 58
Venous (Vein) Thrombosis - Dormant Projects, H2 2014 77
Venous (Vein) Thrombosis - Discontinued Products, H2 2014 78